MedWatch - Smoking cessation aids Chantix, Zyban: Boxed Warning and patient Medication Guides highlighting risk of serious neuropsychiatric symptoms

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: MedWatch - Smoking cessation aids Chantix, Zyban: Boxed Warning and patient Medication Guides highlighting risk of serious neuropsychiatric symptoms
MedWatch logo MedWatch - The FDA Safety Information and Adverse Event Reporting Program

Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
Audience: Neuropsychiatric healthcare professionals, patients

FDA notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products.These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide.The added warnings are based on the continued review of postmarketing adverse event reports for varenicline and bupropion received by the FDA.  These reports included those with a temporal relationship between the use of varenicline or bupropion and suicidal events and the occurrence of suicidal ideation and suicidal behavior in patients with no history of psychiatric disease.
 
Healthcare professionals should advise patients to stop taking varenicline or bupropion and contact a healthcare
provider immediately if they experience agitation, depressed mood, and any changes in behavior that are not typical of nicotine withdrawal, or if they experience suicidal thoughts or behavior.

Read the complete MedWatch 2009 Safety summary, including links to the FDA Public Health Advisory, Information for Healthcare Professionals and previous MedWatch alerts, at:

www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm170090.htm

 


You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm

Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.

This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).

FDA HHS

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420

GovDelivery, Inc. sending on behalf of U.S. Food & Drug Administration (FDA) · 5600 Fishers Lane · Rockville MD 20857 · 800-439-1420


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux